Fred D. Ledley, MD, is Professor in the Department of Natural & Applied Sciences and Department of Management, director of the Center for Integration of Science and Industry at Bentley University, and a Member of Bentley’s Health Thought Leadership Network. A recognized opinion leader in the integration of basic science with medicine, business, society, and education, he is the author of >200 papers in fields ranging from molecular and human biology to drug development, bioethics, and STEM education. Ledley has served on the faculties of the Howard Hughes Medical Institute and the Baylor College of Medicine, and was involved in founding biotechnology companies including GeneMedicine (IPO NASDAQ:GMED), serving as Vice President, R&D, and Variagenics (IPO NASDAQ:VGEN), serving as President & CEO. He has served on the Board of Directors of MassBIO, the Board of Overseers of Boston Children’s Hospital, and as a consultant to industry, academia, and government. He has a BS from the University of Maryland, an MD from Georgetown University, trained in Pediatrics at Boston Children’s Hospital, and was an American Cancer Society fellow with Dr. David Baltimore at MIT.
Laura McNamee, PhD, is a Research Associate in the Center for Integration of Science and Industry and Adjunct Assistant Professor of Natural and Applied Science. McNamee has pioneered an analysis of biotechnology business models based on innovation theories and quantitative analysis of the relationship between the maturation of biomedical technologies, successful drug development, and capital investment. McNamee is a member of Women Entrepreneurs in Science and Technology (WEST) and is active in the Science Club for Girls, an organization dedicated to promoting STEM education and careers for women. McNamee has a BS from Merrimack College and a PhD in Biomedical Sciences from the University of Massachusetts Medical School in Worcester.
Ekaterina (Kat) Galkina Cleary, PhD, is a Research Associate, Lead Data Analyst, at the Center for Integration of Science and Industry at Bentley University. She received her BS in Biology/Bioinformatics from UMass Lowell and MS degree in Bioinformatics from Boston University. She holds a PhD in Biomedical Engineering and Biotechnology from UMass Lowell, where her thesis work focused on statistical modeling of environmental risk factors influencing Alzheimer’s disease progression. Simultaneously, she was project lead on designing an interactive, cartographic visualization of ultrafine particle pollution in the Chinatown region of Boston, MA (an ongoing NIH-funded multi-university project). She is an ambassador for the TZOA wearable air quality tracker and an active member of the Million Women Mentors program. At Bentley she will provide the analytical resources for researching trends in biotech.
Sharotka (Xu) Simon, PhD, is a Research Associate at the Center for Integration of Science and Industry at Bentley University. Dr. Simon completed her BA in Biochemistry at Rice University and her PhD in Biology at MIT. She earned a Kirschstein National Research Service award for her postdoctoral research on neurodegenerative disease at Brandeis University. Xu served two years as a AAAS Science and Technology Policy Fellow, placed in the US Department of State diplomatic office for international chemical threat reduction. She earned her MBA in global business from Bentley University and subsequently served as Executive VP, R&D at Fluid-Screen, Inc. Dr. Simon joined our group to focus on policy issues of translational science and the integration of science and business.
Michael Boss, PhD, MBA, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. Boss has been a leader in the biotechnology industry for more than 30 years as a scientist and senior executive. As a group leader at Celltech, he was lead inventor of the landmark “Boss patent,” which enabled genetic engineering and manufacture of recombinant, monoclonal antibodies and generated >$1 billion in revenues. Dr. Boss co-founded Oros Instruments, a successful developer of protein purification equipment that was acquired by Biotage. He subsequently joined Genica Pharmaceuticals as Vice President of Research and Development and later Vice President of Operations, where he had a central role in building Genica (renamed Athena Diagnostics) into the leading developer of neurological and genetic tests. Most recently, Boss held the position of Vice President, Corporate Office of Technology, at Elan Corporation and Chief Operating Officer of Xanthus Pharmaceuticals Inc., leading its acquisition by Antisoma, where he continued in senior executive positions. For the past five years, Boss has led the program at Summit Therapeutics, Inc. as Chief Technology Officer to develop a therapy for Duchenne Muscular Dystrophy. Under his leadership the program has progressed from pre-clinical to a proof-of-concept Phase 2 trial that is underway. The program received recent validation in a license deal with Sarepta Therapeutics Inc. for European and Latin American commercial rights that Boss negotiated where Summit received $40 million upfront with a total potential deal value of some $941 million in milestone payments. He has a BSc and PhD from London University and an MBA from London Business School, trained in immunology at ICRF London with Dr. Mel Greaves and Dr. Martin Raff, and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT.
Nancy Hsiung, PhD, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. She has more than 30 years of experience in the biotechnology industry, in both scientific and managerial positions as well as in the investment community. For the past 11 years, Hsiung worked with GeneChem Management Inc, a venture fund headquartered in Montreal, where her responsibilities included sourcing, assessing and managing investment opportunities. Prior to GeneChem, Nancy was a consultant whose activities range from strategic planning, business development, technology assessment, market research and financing for biotechnology and biopharmaceutical companies. She started her career on the operational side as a scientist with Integrated Genetics (now part of Genzyme, now Sanofi) where she established the company's gene expression and tissue culture capabilities, as a member of the management team at Applied Biotechnology, whose focus was on vaccines and oncology and as the U.S. head of Corporate Development for Toyobo Corporation's (a large Japanese multinational) biopharmaceutical division. Hsiung received a BA degree from the University of Pennsylvania and a PhD degree in chemistry from Columbia University; she completed her post-doctoral studies in molecular biology at Yale University and Princeton University. She holds more than 15 patents and patent applications worldwide and has written 12 publications/abstracts.
Dr. Mark Adams, PhD, has been working in data analytics for almost 20 years, including work in computational biology, biomedicine, intelligence, finance and biotechnology. He has been right in the middle of the remarkable story of Big Data, in some of the most interesting places where data analytics have been developed and used. He is currently the Chief Information Officer for the biotechnology company Celmatix Inc. in New York City, where he works on the genomics of women's health and infertility. Previous positions included Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world’s largest hedge fund. Dr. Adams has also worked in other medical and biotechnology settings, including almost ten years at Booz Allen Hamilton, where he developed a leading biomedical informatics consulting practice with a primary focus on informatics strategy for clients in the commercial, government, and non-profit markets. From hacking the human genome to protecting the public from bioterrorism, Dr. Adams has led some of the earliest efforts to make sense of Big Data, and is excited to share his experience with everyone. Dr. Adams holds a B.A. from Oberlin College and a PhD from Baylor College of Medicine.
Stephen Atkinson, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. He has 35+ years of experience managing life science technology commercialization in academic and corporate organizations. Since 1997, Mr. Atkinson has been principal of Atkinson & Associates, an international consulting practice specializing in new venture development, technology-based business transactions, project management and intellectual property strategy. He served for nine years as a Senior Consultant for the Copenhagen-based firm, Plougmann Vingtoft. He also served as a consultant to Mount Sinai Innovation Partners at the Icahn School of Medicine at Mount Sinai where he led negotiation of a universal flu vaccine alliance with GlaxoSmithKline. Previously, he was Deputy Director for Business Development at MassBiologics (MBL), where he negotiated an alliance with Merck to commercialize MBL’s C. difficile product. He was Vice President for Commercial Development at Sanofi Pasteur Biologics, where he established and managed government and corporate partnerships. He founded and directed Harvard’s technology development programs, licensing multiple technologies that have been successfully brought to market. He negotiated multiple R&D collaborations with multi-national pharmaceutical firms and was the architect for Medical Science Partners, the Medical School's venture fund. Mr. Atkinson held multiple leadership roles for the Association of University Technology Managers (AUTM), including President, Trustee and Board Member. He has an A.B. from Harvard College and completed intellectual property law, contract and technology commercialization courses at Harvard Law School and Georgetown University.
Current Undergraduate Researchers
Skyler DeBoer '18
Patrick Goldner '19
Prateet Shah '20
Current Graduate Researchers
Navleen Khanuja '18
Qi Xu '19
Janet Yue '19